Suggested remit: To appraise the clinical and cost effectiveness of ozanimod within its marketing authorisation for treating moderately to severely active ulcerative colitis.
Status Proposed
Process STA 2018
ID number 3841

Provisional Schedule

Expected publication 21 September 2022

Project Team

Project lead Emily Richards

Email enquiries


Key events during the development of the guidance:

Date Update
23 July 2021 We recently contacted all stakeholders for the appraisal of Ozanimod for treating moderate to severe ulcerative colitis [ID3841] regarding a delay to this topic for operational reasons. Ozanimod for treating moderate to severe ulcerative colitis has now been rescheduled into the work programme and the appraisal is due to start late October 2021 and will be discussed at committee in mid July 2022. The new timelines are subject to the work programme capacity and we will continue to review our plans and update our stakeholders accordingly.
13 May 2021 Timelines for this appraisal are to be confirmed. Further information regarding the scheduling of this appraisal will be available in due course.
27 January 2021 - 24 February 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance